We are working on developing PI3-K predictive pharmacodynamic biomarkers, as well as CDK4/6 inhibitors.  Revealing new mechanisms of resistance against BRCA1/2 germline therapy in breast cancer, and establishing a preclinical model of patients with breast cancer, to explore the hypotheses based on combination therapies.

Visit the research group’s page

Centres
General Hospital
Vall d'Hebron Institute of Oncology
Serveis
Medical Oncology
Ponderació
9
Recerca
Grup de terapèutica experimental
Enllaç
https://vhio.net/pf/experimental-therapeutics-group/

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.